Transplantology,
Год журнала:
2024,
Номер
5(3), С. 224 - 233
Опубликована: Сен. 18, 2024
Sodium
glucose
cotransporter
type
2
inhibitors
are
a
new
class
of
drugs
that
act
on
the
cardiovascular
system,
kidneys
and
metabolism
in
multiple
ways.
Indeed,
even
though
their
principal
action
involves
transport
sodium
convoluted
distal
tubule,
they
have
actions,
such
as
antifibrotic
endothelial
protective
effects.
Their
mechanism
consists
loss
glucose.
Therefore,
affect
blood
pressure
metabolism.
first
use
was
diabetic
general
population;
later,
some
studies
documented
activity
nondiabetic
population
heart
failure
chronic
kidney
disease
patients.
Only
recent
years
several
small
efficacy
these
transplant
patients;
relatively
large
rare,
very
recent,
open
routes
for
development
drugs.
Journal of Clinical & Translational Endocrinology,
Год журнала:
2024,
Номер
35, С. 100335 - 100335
Опубликована: Март 1, 2024
Multiple
randomized
controlled
trials
have
extensively
examined
the
therapeutic
effectiveness
of
sodium-glucose
cotransporter
2
(SGLT2)
inhibitors,
ushering
in
a
transformative
approach
to
treating
individuals
with
type
diabetes
mellitus
(DM).
Notably,
emerging
reports
drawn
attention
potential
positive
impacts
SGLT2
inhibitors
nondiabetic
patients.
In
an
effort
delve
into
this
phenomenon,
comprehensive
systematic
literature
review
spanning
PubMed
(NLM),
Medline
(Ovid),
and
Cochrane
Library,
covering
publications
from
2000
2024
was
undertaken.
This
encompassed
twenty-six
control
(RCTs)
involving
35,317
participants.
The
findings
unveiled
multifaceted
role
for
showcasing
their
ability
enhance
metabolic
yield
cardioprotective
effects
through
reduction
cardiovascular
death
(CVD)
hospitalization
related
heart
failure
(HF).
Additionally,
renalprotective
effect
observed,
evidenced
by
slowdown
chronic
kidney
disease
(CKD)
progression
decrease
albuminuria.
Importantly,
these
benefits
were
coupled
acceptable
safety
profile.
also
points
various
biological
plausibility
underlying
mechanistic
pathways,
offering
insights
association
between
outcomes
individuals.
Current
research
trends
indicate
continual
exploration
additional
in.
Nevertheless,
further
is
imperative
fully
elucidate
mechanisms
long-term
associated
use
inhibitors.
The Lancet Regional Health - Europe,
Год журнала:
2024,
Номер
45, С. 101032 - 101032
Опубликована: Авг. 23, 2024
SummaryBackgroundSodium-glucose
co-transporter
2
(SGLT2)
inhibitors
have
been
shown
to
reduce
rates
of
heart
failure
hospitalisations
and
cardiovascular
death
in
patients
with
type
diabetes
prior
disease.
We
hypothesised
that
SGLT2
could
provide
benefits
the
post-myocardial
infarction
setting.
aimed
investigate
outcomes
inhibitor
therapy
mellitus
after
myocardial
a
Swedish
nationwide
registry.MethodsWe
included
all
surviving
1
acute
from
January
1,
2018
December
31,
2021.
Patients
were
if
they
discharged
an
estimated
glomerular
filtration
rate
(eGFR)
>
30
mL/min/1.73
m2
Web-system
for
Enhancement
Development
Evidence-based
care
Heart
disease
Evaluated
According
Recommended
Therapies
(SWEDEHEART)
registry.
identified
or
without
prescription
120
days
before
within
three
discharge
cardiac
unit.
The
primary
outcome
measure
was
composite
first
hospitalisation
one
year
analysed
using
adjusted
Cox
regression.FindingsA
total
11,271
included.
Of
these,
2498
(22.2%)
received
treatment.
who
prescribed
younger,
more
often
presented
STEMI
had
worse
left
ventricular
ejection
fraction
at
index
hospitalisation.
use
associated
lower
(hazard
ratio
(HR)
0.70
(95%
confidence
interval
(CI)
0.59–0.82).InterpretationTreatment
events.FundingThis
work
supported
by
Hjärt-Lungfonden,
Vetenskapsrådet,
Knut
Alice
Wallenberg
Foundation,
ALF,
Bundy
Academy,
Skåne
University
Hospital
funds.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(13), С. 7057 - 7057
Опубликована: Июнь 27, 2024
Chronic
kidney
disease
(CKD)
is
a
noncommunicable
condition
that
has
become
major
healthcare
burden
across
the
globe,
often
underdiagnosed
and
associated
with
low
awareness.
The
main
cause
leads
to
development
of
renal
impairment
diabetes
mellitus
and,
in
contrast
other
chronic
complications
such
as
retinopathy
or
neuropathy,
it
been
suggested
intensive
glycemic
control
not
sufficient
preventing
diabetic
disease.
Nevertheless,
novel
class
antidiabetic
agents,
sodium-glucose
cotransporter-2
inhibitors
(SGLT2i),
have
shown
multiple
renoprotective
properties
range
from
metabolic
hemodynamic
direct
effects,
impact
on
reducing
risk
occurrence
progression
CKD.
Thus,
this
review
aims
summarize
current
knowledge
regarding
mechanisms
SGLT2i
offer
new
perspective
innovative
antihyperglycemic
drugs
proven
pleiotropic
beneficial
effects
that,
after
decades
no
significant
progress
prevention
delaying
decline
function,
start
era
management
patients
Nephrology Dialysis Transplantation,
Год журнала:
2023,
Номер
39(2), С. 202 - 214
Опубликована: Авг. 21, 2023
ABSTRACT
Among
the
broad
spectrum
of
membranoproliferative
glomerulonephritis
(MPGN),
immunofluorescence
distinguishes
C3
glomerulopathy
(C3G),
with
predominant
deposits,
and
immunoglobulin-associated
MPGN
(Ig-MPGN),
combined
Ig.
However,
there
are
several
intersections
between
C3G
Ig-MPGN.
Primary
Ig-MPGN
share
same
prevalence
low
serum
levels
abnormalities
alternative
pathway
complement,
patients
who
present
a
bioptic
pattern
at
onset
may
show
in
subsequent
biopsy.
There
is
no
specific
therapy
for
primary
prognosis
unfavourable.
The
only
recommended
indications
inhibitors
renin–angiotensin
system,
lipid-lowering
agents
other
renoprotective
agents.
drugs
used
currently,
such
as
corticosteroids
mycophenolate
mofetil,
often
ineffective.
anti-C5
monoclonal
antibody
eculizumab
has
been
tested
patients,
mixed
results.
One
reason
uncertainty
extremely
variable
clinical
course,
most
likely
reflecting
heterogeneous
pathogenesis.
An
unsupervised
clustering
analysis
that
included
histologic,
biochemical,
genetic
data
available
identified
four
clusters
characterized
by
pathogenic
mechanisms.
This
approach
facilitate
accurate
diagnosis
development
targeted
therapies.
Several
trials
ongoing
targeting
different
molecules
complement
cascade,
however
it
important
to
consider
which
component
cascade
be
appropriate
each
patient.
We
review
current
standards
treatment
discuss
novel
developments
pathophysiology,
diagnosis,
outcome
prediction
management
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(4), С. 956 - 956
Опубликована: Фев. 7, 2024
Sodium-glucose
cotransporter
2
inhibitors
(SGLT2i)
are
currently
available
for
the
management
of
type
diabetes
mellitus.
SGLT2i
acts
by
inhibiting
renal
SGLT2,
thereby
increasing
glucosuria
and
lowering
serum
glucose.
Recent
trials
emerging
supporting
a
role
irrespective
diabetic
status
pointing
towards
that
have
other
mechanisms
actions
beyond
blood
sugar
control.
In
this
review,
we
will
shed
light
on
group
medications
act
as
in
non-diabetics
focusing
pre-clinical
clinical
data
highlighting
mechanism
renoprotection
effects
non-diabetic
kidneys.
Scientific Reports,
Год журнала:
2023,
Номер
13(1)
Опубликована: Ноя. 6, 2023
Abstract
Sodium-glucose
co-transporters
(SGLTs)
in
the
kidneys
play
a
pivotal
role
glucose
reabsorption.
Several
clinical
and
population-based
studies
revealed
beneficial
effects
of
SGLT2
inhibition
on
hypertension.
Recent
work
from
our
lab
provided
significant
new
insight
into
non-diabetic
model
salt-sensitive
hypertension,
Dahl
(SS)
rats.
Dapagliflozin
(Dapa)
blunted
development
salt-induced
hypertension
by
causing
glucosuria
natriuresis
without
changes
Renin–Angiotensin–Aldosterone
System.
However,
initial
study
used
male
SS
rats
only,
effect
inhibitors
females
has
not
been
studied.
Therefore,
goal
this
was
to
determine
whether
alters
blood
pressure
kidney
function
female
The
result
showed
that
administration
Dapa
for
3
weeks
prevented
progression
rats,
similar
its
Diuresis
excretion
were
significantly
increased
Dapa-treated
also
attenuated
but
heart
fibrosis.
Despite
pressure,
treatment
caused
minor
electrolyte
balance
no
weights
observed.
Our
data
suggest
blunts
independent
sex.
Biomedicines,
Год журнала:
2024,
Номер
12(7), С. 1507 - 1507
Опубликована: Июль 7, 2024
(1)
Background:
The
validation
of
new
lines
therapy
for
the
elderly
is
required
due
to
progressive
ageing
world
population
and
scarce
evidence
in
patients
with
HF
reduced
ejection
fraction
(HFrEF).
purpose
our
study
analyze
effect
SGLT2
inhibitors
(SGLT2i)
this
subgroup
patients.
(2)
Methods:
A
single-center,
real-world
observational
was
performed.
We
consecutively
enrolled
all
aged
≥
75
years
diagnosed
HFrEF
treatment
SGLT2i,
considered
theoretical
indications.
(3)
Results:
total
364
were
recruited,
a
mean
age
84.1
years.
At
inclusion,
LVEF
29.8%.
Median
follow-up
33
months,
there
122
deaths.
55
under
SGLT2i
treatment.
multivariate
Cox
logistic
regression
test
all-cause
mortality
performed,
only
(HR
0.39
[0.19–0.82])
glomerular
filtration
rate
0.98
[0.98–0.99])
proved
be
protective
factors.
In
parallel,
we
conducted
propensity-score-matched
analysis,
where
significant
reduction
associated
use
0.39,
[0.16–0.97]).
(4)
Conclusions:
Treatment
lower
mortality.
Our
data
show
that
could
improve
prognosis
study.
